 | |
 |
Israel's Compugen Completes Stage Two of Agreement with Warner-Lambert's
Pharmaceutics Division
Compugen of Tel Aviv, which develops advanced computation technologies for
the description and comprehension of life's molecular mechanisms, announced
that it has completed the second stage (which it designates "milestone") in
its Leads platform agreement signed with Parke-Davis. Parke-Davis is the
pharmaceutics division of the US Lambert-Warner group. The volume of the
agreement is several millions of dollars. Compugen will receive payment for
its achievements, although how much is not known.
Leads is a biological computation platform for describing and understanding
life's molecular mechanisms. Compugen Chairman Martin Gerstel said the
achievement would make tools available for extracting significant
information from gnomic and other databases.
Compugen's scientists have already discovered more than 4,000 previously
unknown new human genes. The company recently launched LabOnWeb labonweb
(http://www.labonweb.com) the first research engine in the Internet
network, which provides researchers worldwide with an analysis of
experiment-derived biological information.
Published by Israel's Business Arena December 26, 1999
|
